JP5395437B2 - ステロイド化合物の治療使用 - Google Patents

ステロイド化合物の治療使用 Download PDF

Info

Publication number
JP5395437B2
JP5395437B2 JP2008540695A JP2008540695A JP5395437B2 JP 5395437 B2 JP5395437 B2 JP 5395437B2 JP 2008540695 A JP2008540695 A JP 2008540695A JP 2008540695 A JP2008540695 A JP 2008540695A JP 5395437 B2 JP5395437 B2 JP 5395437B2
Authority
JP
Japan
Prior art keywords
pain
galanin
nerve
neuropathic
injury
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
JP2008540695A
Other languages
English (en)
Japanese (ja)
Other versions
JP2009515939A5 (https=
JP2009515939A (ja
Inventor
ヴュルフェルト、エルンスト
マレイ、ジェイムズ・ロバート
ウィニック、デイヴィッド
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Hunter Fleming Ltd
Original Assignee
Hunter Fleming Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Hunter Fleming Ltd filed Critical Hunter Fleming Ltd
Publication of JP2009515939A publication Critical patent/JP2009515939A/ja
Publication of JP2009515939A5 publication Critical patent/JP2009515939A5/ja
Application granted granted Critical
Publication of JP5395437B2 publication Critical patent/JP5395437B2/ja
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/565—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol
    • A61K31/568—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol substituted in positions 10 and 13 by a chain having at least one carbon atom, e.g. androstanes, e.g. testosterone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
    • A61K31/573—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone substituted in position 21, e.g. cortisone, dexamethasone, prednisone or aldosterone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biomedical Technology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Hospice & Palliative Care (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Psychology (AREA)
  • Psychiatry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Steroid Compounds (AREA)
JP2008540695A 2005-11-18 2006-11-17 ステロイド化合物の治療使用 Expired - Fee Related JP5395437B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GB0523550.2 2005-11-18
GBGB0523550.2A GB0523550D0 (en) 2005-11-18 2005-11-18 Therapeutic uses of steroidal compounds
PCT/GB2006/004305 WO2007057691A2 (en) 2005-11-18 2006-11-17 Therapeutic uses of steroidal compounds

Publications (3)

Publication Number Publication Date
JP2009515939A JP2009515939A (ja) 2009-04-16
JP2009515939A5 JP2009515939A5 (https=) 2012-11-08
JP5395437B2 true JP5395437B2 (ja) 2014-01-22

Family

ID=35580318

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2008540695A Expired - Fee Related JP5395437B2 (ja) 2005-11-18 2006-11-17 ステロイド化合物の治療使用

Country Status (16)

Country Link
US (1) US8846652B2 (https=)
EP (1) EP1948192A2 (https=)
JP (1) JP5395437B2 (https=)
KR (1) KR101314694B1 (https=)
CN (1) CN101346144B (https=)
AU (1) AU2006314226B2 (https=)
CA (1) CA2630441C (https=)
GB (1) GB0523550D0 (https=)
IL (1) IL191457A (https=)
MX (1) MX2008006440A (https=)
NO (1) NO20082741L (https=)
NZ (1) NZ568560A (https=)
RU (1) RU2427375C2 (https=)
TW (1) TWI386211B (https=)
WO (1) WO2007057691A2 (https=)
ZA (1) ZA200804266B (https=)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CU20110244A7 (es) 2011-12-27 2013-08-29 Ct De Investigación Y Desarrollo De Medicamentos Cidem Sistemas espiroesteroidales con efectos neuroactivos y anti-inflamatorios
CN108434090A (zh) * 2017-02-14 2018-08-24 高药品股份有限公司 以生理脂肪为基剂的类固醇药膏
RU2745868C9 (ru) * 2020-05-28 2021-04-08 Федеральное государственное бюджетное образовательное учреждение высшего образования «Национальный исследовательский Мордовский государственный университет им. Н.П. Огарёва» Способ ускорения регенерационных процессов в поврежденных периферических нервах

Family Cites Families (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1992012997A1 (en) 1991-01-16 1992-08-06 The General Hospital Corporation Human galanin
WO1992015015A1 (en) 1991-02-25 1992-09-03 Zymogenetic, Inc. Methods for detecting galanin antagonists
DE69225706T2 (de) 1991-03-06 1998-11-26 Garvan Institute Of Medical Research, Darlinghurst, Neu Sued Wales/New South Wales Humanes galanin, cdna-klone die für humanes galanin kodieren und eine methode humanes galamin herzustellen
SE9101472D0 (sv) 1991-05-15 1991-05-15 Trion Forskning & Utveckling Galanin antagonist
JPH06172387A (ja) 1992-12-11 1994-06-21 Aibaitsu Kk 合成ペプチド誘導体
EP0698612B1 (en) * 1993-05-18 2001-07-25 Ltt Institute Co., Ltd. Osteogenesis promoter and osteoporosis remedy
JPH09151197A (ja) * 1995-11-29 1997-06-10 L T T Kenkyusho:Kk 自己免疫疾患治療薬
DE69739760D1 (de) 1996-07-24 2010-03-25 Neurotargets Ltd Verwendung eines Galanin-agonisten in der Herstellung eines Medikaments zur Verbesserung des Gedächtnisses und anderer cognitiver Funktionen
JP2000169374A (ja) * 1998-12-03 2000-06-20 Ltt Kenkyusho:Kk Ｉｇｆ増強剤
TR200200406T2 (tr) * 1999-06-11 2002-06-21 Watson Pharmaceuticals, Inc. Kadınlara oral olmayan yollarla androjenik steroidlerin uygulanması
DE10054294A1 (de) * 2000-11-02 2002-05-16 Heinrich Wieland Topische Behandlung bei der Mastalgie
GB0105772D0 (en) * 2001-03-08 2001-04-25 Sterix Ltd Use
DE60120104T2 (de) 2001-03-20 2006-09-21 Schwarz Pharma Ag Neue Verwendung von Peptidverbindungen bei der Behandlung von nicht-neuropathischem Entzündungsschmerz
WO2002096934A1 (en) 2001-05-25 2002-12-05 Kemia, Inc. Non-natural galanin receptor ligands
DK1406606T3 (da) 2001-07-16 2007-03-05 Ortho Mcneil Pharm Inc Carbamatforbindelser til forebyggelse eller behandling af neuropatisk smerte og smerte forbundet med klynge- og migrænehovedpine
JP2004538305A (ja) 2001-07-31 2004-12-24 ファルマシア・アンド・アップジョン・カンパニー ３−ヘテロシクリル−及び３−シクロアルキル−３−アリールオキシプロパンアミンによる慢性疼痛の治療
WO2003011272A1 (en) 2001-07-31 2003-02-13 Pharmacia & Upjohn Company Treatment of chronic pain with 3-aryloxy-3-phenylpropanamines
ATE332688T1 (de) 2001-10-16 2006-08-15 Endo Pharmaceuticals Inc Verwendung von carbinolen zur behandlung von neuropathischer funktionsstörung
GB0403509D0 (en) 2004-02-17 2004-03-24 Neuro Targets Ltd Galanin receptors and brain injury
US20070231373A1 (en) * 2004-04-28 2007-10-04 Hunter-Fleming Limited Transdermal Steriod for Formulation
JP5449775B2 (ja) * 2005-10-19 2014-03-19 チャバフ ピーティーワイ エルティーディー 乳癌の治療に使用されるアロマターゼ阻害薬による副作用の低減
WO2008065408A2 (en) 2006-11-30 2008-06-05 Hunter-Fleming Limited Modulation of prostaglandin/cyclooxygenase metabolic pathways

Also Published As

Publication number Publication date
US8846652B2 (en) 2014-09-30
MX2008006440A (es) 2008-12-01
RU2008124834A (ru) 2009-12-27
WO2007057691A2 (en) 2007-05-24
TW200730180A (en) 2007-08-16
NZ568560A (en) 2010-11-26
CN101346144A (zh) 2009-01-14
IL191457A (en) 2013-10-31
AU2006314226A1 (en) 2007-05-24
WO2007057691A3 (en) 2007-08-02
CA2630441C (en) 2013-10-29
CN101346144B (zh) 2011-07-20
US20090227551A1 (en) 2009-09-10
ZA200804266B (en) 2009-01-28
CA2630441A1 (en) 2007-05-24
GB0523550D0 (en) 2005-12-28
JP2009515939A (ja) 2009-04-16
TWI386211B (zh) 2013-02-21
IL191457A0 (en) 2009-08-03
KR101314694B1 (ko) 2013-10-07
NO20082741L (no) 2008-07-23
KR20080073755A (ko) 2008-08-11
RU2427375C2 (ru) 2011-08-27
EP1948192A2 (en) 2008-07-30
AU2006314226B2 (en) 2012-02-02

Similar Documents

Publication Publication Date Title
JP3089350B2 (ja) シクロフィリンロタマーゼ活性の阻害剤
CN105073110A (zh) 通过诱导分化成调节性t细胞和促进调节性t细胞增殖来抑制免疫应答的药物组合物
Wang et al. Human breast milk-derived exosomes protect against intestinal ischemia and reperfusion injury in neonatal rats
AU2003250892B2 (en) Use of alanyl-aminopeptidase inhibitors and pharmaceutical compositions containing said inhibitors
US20220340659A1 (en) Activity Modulator
AU2004275682A1 (en) Novel use of antisecretory factor
EP3856187A1 (en) Infigratinib for treatment of fgfr3-related skeletal diseases during pregnancy
AU2013271841B2 (en) Method of prevention of neurological diseases
JP5395437B2 (ja) ステロイド化合物の治療使用
EP0610336A1 (en) Treatment of neurological conditions by an interleukin-1 inhibiting compound
McNeil et al. Reversal of ethanol and indomethacin‐induced suppression of hepatic DNA synthesis by 16, 16‐dimethyl prostaglandin E2
JP2009515939A5 (https=)
PT1737490E (pt) Processos de tratamento da aterosclerose
JP4942905B2 (ja) 神経保護活性を有する７−ヒドロキシエピアンドロステロン
CN116115760A (zh) Eed抑制剂在制备治疗神经免疫性疾病药物中的应用
RU2721282C2 (ru) Способ лечения рассеянного склероза (варианты)
KR101277873B1 (ko) Ｎｉｎｊｕｒｉｎ 활성 억제제를 포함하는 신경세포 또는 내피세포 재생용 조성물
EP3700534B1 (en) Methods of treating phelan mcdermid syndrome using farnesyl dibenzodiazepinones
WO2007123234A1 (ja) 抗てんかん作用増強剤
Tong et al. GHRHR Deficiency Enhances Retinal Ganglion Cell Survival and Visual Functions in Experimental Glaucoma by Inhibiting Ferroptosis
CN104436166A (zh) 神经生长因子在制备治疗脊髓损伤药物中的应用
JP2016509590A (ja) 加齢に伴う障害の治療のための組換え７型コラーゲンの投与
HK40060507B (zh) 包含环（组氨酸-脯氨酸）二肽及甲状旁腺激素的组合物用於预防、改善或治疗骨质流失疾病的用途
HK40032147A (en) Activity modulator

Legal Events

Date Code Title Description
A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20091112

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20120619

A524 Written submission of copy of amendment under article 19 pct

Free format text: JAPANESE INTERMEDIATE CODE: A524

Effective date: 20120919

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20130312

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20130612

A602 Written permission of extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A602

Effective date: 20130619

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20130709

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20131008

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20131018

R150 Certificate of patent or registration of utility model

Free format text: JAPANESE INTERMEDIATE CODE: R150

LAPS Cancellation because of no payment of annual fees